Whalesbook
Star Health and Allied Insurance Company Ltd.'s latest financial report highlights operational efficiency, especially in underwriting. This performance has led analysts, including Motilal Oswal, to maintain a positive outlook. The company's net earned premium (NEP) rose 14% year-over-year to INR 43.3 billion in Q4 FY26, reflecting strong growth in the health insurance sector influenced by regulatory changes and greater health awareness.
Strong Underwriting and Analyst Support
The company reported significant improvements in Q4 FY26: its claims ratio dropped to 64.8% (down 440 basis points year-over-year) and the commission ratio fell to 14.2% (down 150 basis points). While the expense ratio increased by 160 basis points to 15.8%, the overall combined ratio improved by 440 basis points year-over-year to 94.8%. This strong underwriting performance led Motilal Oswal Securities to reaffirm its 'BUY' rating and INR 640 price target. The brokerage forecasts a 32% compound annual growth rate for IFRS Profit After Tax (PAT) from FY26 to FY28, signaling confidence in Star Health's operational strengths.
Valuation Concerns
Despite positive results and analyst backing, Star Health's valuation is a major concern. Its Price-to-Earnings (P/E) ratio, trading between 56x and 70x as of April 2026, makes it a premium-priced stock. This is significantly higher than peers like Niva Bupa (46.7x) and Go Digit (57.8x), and far exceeds the Asian Insurance industry average of about 11.6x. The current P/E also represents a substantial increase from its historical levels, such as 31.3x at the end of 2025. This high valuation implies strong market expectations for future growth are already factored into the stock price.
Market Growth and Regulatory Shifts
The Indian health insurance market is growing strongly, forecast to expand from USD 15.76 billion in 2025 to USD 32.21 billion by 2034, a compound annual growth rate of 8.27%. Premiums increased by 27.17% year-over-year in January 2026, partly due to Goods and Services Tax (GST) rationalization reducing taxes on retail policies. Regulatory changes, like the 100% foreign direct investment (FDI) cap and mandatory adoption of Indian Accounting Standards (Ind AS 117) from April 1, 2026, are modernizing the market and boosting competition. These shifts foster growth but also demand adaptation to new reporting standards.
Mixed Analyst Views
Analyst sentiment on Star Health is mixed. While Motilal Oswal Securities reiterates a 'BUY' rating with a INR 640 target, other consensus price targets average around INR 528-530. Notably, some analysts have issued 'Strong Sell' ratings, citing fundamental concerns. This divergence highlights differing views on Star Health's operational performance, growth potential, and long-term financial health.
Key Risks and Concerns
Despite strong underwriting and growth forecasts, several factors call for investor caution. Star Health's valuation, with a P/E ratio far exceeding industry averages and its historical range, appears stretched. This high valuation depends on continued high growth, which may be challenging in a more competitive market. While recent expense ratio increases were offset by other gains, they could impact profitability if not controlled. The significant number of 'Strong Sell' ratings from analysts also points to potential underlying risks not fully reflected in positive outlooks. For example, an unexpected INR 16.51 crore gratuity expense in Q3 FY26 due to new labor code definitions shows how unforeseen costs can affect earnings. Increased sector competition could also pressure Star Health's pricing power and market share.
Outlook Remains Challenging
Star Health operates in a rapidly growing Indian health insurance market. Analysts expect continued expansion fueled by rising health awareness, incomes, and government support. The company's focus on technology and efficiency, shown in its Q4 FY26 results, aims to maintain its market leadership. However, sustaining its growth rate and justifying its high valuation remain key challenges. Investors will watch how Star Health performs against ambitious targets and navigates regulatory shifts and competition.